Beijing Friendship Hospital: Liver Cirrhosis trials

The registry lists 15 Liver Cirrhosis studies with Beijing Friendship Hospital as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 3 1Phase 4 4No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Non-Invasive Model for Fibrosis Regression in HBV PatientsRecruitingNCT06874127
• The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related CirrhosisNot yet recruitingNCT06773221Not applicable
• Precise Evaluation Criteria for Histological Regression of NASH FibrosisNot yet recruitingNCT06364462
• Prevention of HCC Using Mobile Phone ApplicationsStatus unknownNCT05094869
• Re-compensation and Its Clinical Characteristics in HBV Decompensated CirrhosisStatus unknownNCT05086536
• Extension Study of Carvedilol RCT StudyStatus unknownNCT05021406Not applicable
• Carvedilol for Prevention of Esophageal Varices ProgressionStatus unknownNCT03736265Not applicable
• Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver FibrosisStatus unknownNCT03386890
• Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis PatientsActive, not recruitingNCT02849132Phase 4
• Optimized Treatment and Regression of HBV-induced Compensated Liver CirrhosisCompletedNCT01943617Phase 4
• Optimized Treatment and Regression of HBV-induced Early CirrhosisCompletedNCT01938820Phase 4
• Optimized Treatment and Regression of HBV-induced Liver FibrosisCompletedNCT01938781Phase 4
• Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary CirrhosisCompletedNCT01857284Phase 3
• Efficacy and Safety of Tolvaptan in Cirrhotic Patients With HyponatremiaCompletedNCT01850940
• Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver CirrhosisStatus unknownNCT01720238